Studies including age-stratified patients (from the onset to longer disease durations), as well as longitudinal studies are needed to assess over time the CAC of PD patients with GBA mutations, in order to clarify the dynamics of disease progression in this subgroup. Here, GBA1 is linked to Parkinson disease.